Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2022

02-05-2022 | Oral Cancer | Review – Cancer Research

Current trends of targeted therapy for oral squamous cell carcinoma

Authors: Hongjiao Li, Yao Zhang, Mengmeng Xu, Deqin Yang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2022

Login to get access

Abstract

Oral squamous cell carcinoma (OSCC) is a malignant disease in the world which has a profound effect on human health and life quality. According to tumor stage and pathological diagnosis, OSCC is mainly treated by combinations of surgery, radiotherapy and chemotherapy. However, traditional treatment methods suffer from some limitations, such as systemic toxicity, limited therapeutic effect and drug resistance. With the rapid development of nanotechnology, nanodrug delivery systems (DDSs) and intelligent DDSs have been widely used in targeted therapy for OSCC. Meanwhile, the newly developed therapeutic techniques such as immunotherapy, gene therapy and bionic technology provide the possibility to realize the active targeted therapy. Here, the latest advances of target therapy for OSCC are reviewed, and their therapeutic remarks, current limits and future prospects are also systematically interpreted. It is believed that active and passive targeted therapies have great potentials for clinical transformation and application of OSCC, which will greatly improve human quality of life.
Literature
go back to reference Baselga J, Trigo J, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577. https://doi.org/10.1200/JCO.2005.07.119CrossRefPubMed Baselga J, Trigo J, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577. https://​doi.​org/​10.​1200/​JCO.​2005.​07.​119CrossRefPubMed
go back to reference Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578. https://doi.org/10.1056/NEJMoa053422CrossRefPubMed Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578. https://​doi.​org/​10.​1056/​NEJMoa053422CrossRefPubMed
go back to reference Boonkitticharoen V, Kulapaditharom B, Leopairut J, Kraiphibul P, Larbcharoensub N, Cheewaruangroj W, Chintrakarn C, Pochanukul L (2008) Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma. Arch Otolaryngol-Head Neck Surg 134:1305–1311. https://doi.org/10.1001/archotol.134.12.1305CrossRefPubMed Boonkitticharoen V, Kulapaditharom B, Leopairut J, Kraiphibul P, Larbcharoensub N, Cheewaruangroj W, Chintrakarn C, Pochanukul L (2008) Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma. Arch Otolaryngol-Head Neck Surg 134:1305–1311. https://​doi.​org/​10.​1001/​archotol.​134.​12.​1305CrossRefPubMed
go back to reference De Oliveira M, Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, Mcarthur MJ, Bell D, William WN, Heymach JV (2021) Targeting of CD40 and PD-L1 pathways inhibits progression of oral premalignant lesions in a carcinogen-induced model of oral squamous cell carcinoma. Cancer Prev Res 14:313–324. https://doi.org/10.1158/1940-6207.CAPR-20-0418CrossRef De Oliveira M, Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, Mcarthur MJ, Bell D, William WN, Heymach JV (2021) Targeting of CD40 and PD-L1 pathways inhibits progression of oral premalignant lesions in a carcinogen-induced model of oral squamous cell carcinoma. Cancer Prev Res 14:313–324. https://​doi.​org/​10.​1158/​1940-6207.​CAPR-20-0418CrossRef
go back to reference Heery CR, O’sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot J-M, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL (2017) Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–598. https://doi.org/10.1016/S1470-2045(17)30239-5CrossRefPubMedPubMedCentral Heery CR, O’sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot J-M, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL (2017) Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–598. https://​doi.​org/​10.​1016/​S1470-2045(17)30239-5CrossRefPubMedPubMedCentral
go back to reference Huang Q, Yu GP, Mccormick SA, Mo J, Datta B, Mahimkar M, Lazarus P, Schäffer AA, Desper R, Schantz SP (2002) Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosom Cancer 34:224–233. https://doi.org/10.1002/gcc.10062CrossRefPubMed Huang Q, Yu GP, Mccormick SA, Mo J, Datta B, Mahimkar M, Lazarus P, Schäffer AA, Desper R, Schantz SP (2002) Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosom Cancer 34:224–233. https://​doi.​org/​10.​1002/​gcc.​10062CrossRefPubMed
go back to reference Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D’egidio M, Adamo V, Natoli C, Rabinovich GA, Iacobelli S, Nifantiev NE, The Consorzio Interuniversitario Nazionale Per La Bio-Oncologia I (2009) Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 29: 403–410. https://ar.iiarjournals.org/content/anticanres/29/1/403.full.pdf. Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D’egidio M, Adamo V, Natoli C, Rabinovich GA, Iacobelli S, Nifantiev NE, The Consorzio Interuniversitario Nazionale Per La Bio-Oncologia I (2009) Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 29: 403–410. https://​ar.​iiarjournals.​org/​content/​anticanres/​29/​1/​403.​full.​pdf.
go back to reference Kaminskas LM, Mcleod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M, Owen DJ, Porter C (2012) A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. nanomedicine: nanotechnology. Biol Med 8:103–111. https://doi.org/10.1016/j.nano.2011.05.013CrossRef Kaminskas LM, Mcleod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M, Owen DJ, Porter C (2012) A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. nanomedicine: nanotechnology. Biol Med 8:103–111. https://​doi.​org/​10.​1016/​j.​nano.​2011.​05.​013CrossRef
go back to reference Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England J Med 359:1116–1127. https://doi.org/10.1056/NEJMoa0802656CrossRef Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England J Med 359:1116–1127. https://​doi.​org/​10.​1056/​NEJMoa0802656CrossRef
go back to reference Wang D, Xu X, Zhang K, Sun B, Wang L, Meng L, Liu Q, Zheng C, Yang B, Sun H (2017a) Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int J Nanomed 13:187–198. https://doi.org/10.2147/IJN.S150610CrossRef Wang D, Xu X, Zhang K, Sun B, Wang L, Meng L, Liu Q, Zheng C, Yang B, Sun H (2017a) Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int J Nanomed 13:187–198. https://​doi.​org/​10.​2147/​IJN.​S150610CrossRef
go back to reference Wang H-H, Fu Z-G, Li W, Li Y-X, Zhao L-S, Wen L, Zhang J-J, Wen N (2019b) The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma. Int J Nanomed 14:623. https://doi.org/10.2147/IJN.S217586CrossRef Wang H-H, Fu Z-G, Li W, Li Y-X, Zhao L-S, Wen L, Zhang J-J, Wen N (2019b) The synthesis and application of nano doxorubicin-indocyanine green matrix metalloproteinase-responsive hydrogel in chemophototherapy for head and neck squamous cell carcinoma. Int J Nanomed 14:623. https://​doi.​org/​10.​2147/​IJN.​S217586CrossRef
go back to reference Wang Y, Xie D, Pan J, Xia C, Fan L, Pu Y, Zhang Q, Ni YH, Wang J, Hu Q (2019d) A near infrared light-triggered human serum albumin drug delivery system with coordination bonding of indocyanine green and cisplatin for targeting photochemistry therapy against oral squamous cell cancer. Biomater Sci 7:5270–5282. https://doi.org/10.1039/C9BM01192GCrossRefPubMed Wang Y, Xie D, Pan J, Xia C, Fan L, Pu Y, Zhang Q, Ni YH, Wang J, Hu Q (2019d) A near infrared light-triggered human serum albumin drug delivery system with coordination bonding of indocyanine green and cisplatin for targeting photochemistry therapy against oral squamous cell cancer. Biomater Sci 7:5270–5282. https://​doi.​org/​10.​1039/​C9BM01192GCrossRefPubMed
go back to reference Wei Z, Yin X, Cai Y, Xu W, Song C, Wang Y, Zhang J, Kang A, Wang Z, Han W (2018) Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma. Int J Nanomed 13:1505–1524. https://doi.org/10.2147/ijn.S156984CrossRef Wei Z, Yin X, Cai Y, Xu W, Song C, Wang Y, Zhang J, Kang A, Wang Z, Han W (2018) Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma. Int J Nanomed 13:1505–1524. https://​doi.​org/​10.​2147/​ijn.​S156984CrossRef
go back to reference Zhou Z-H, Liang S-Y, Zhao T-C, Chen X-Z, Cao X-K, Qi M, Huang Y-Y, Ju W-T, Yang M, Zhu D-W, Pang Y-C, Zhong L-P (2021) Overcoming chemotherapy resistance using pH-sensitive hollow MnO2 nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma. J Nanobiotechnology 19:1–14. https://doi.org/10.1186/s12951-021-00901-9CrossRef Zhou Z-H, Liang S-Y, Zhao T-C, Chen X-Z, Cao X-K, Qi M, Huang Y-Y, Ju W-T, Yang M, Zhu D-W, Pang Y-C, Zhong L-P (2021) Overcoming chemotherapy resistance using pH-sensitive hollow MnO2 nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma. J Nanobiotechnology 19:1–14. https://​doi.​org/​10.​1186/​s12951-021-00901-9CrossRef
Metadata
Title
Current trends of targeted therapy for oral squamous cell carcinoma
Authors
Hongjiao Li
Yao Zhang
Mengmeng Xu
Deqin Yang
Publication date
02-05-2022
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2022
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-022-04028-8

Other articles of this Issue 9/2022

Journal of Cancer Research and Clinical Oncology 9/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine